LCB 09A
Alternative Names: LCB-09ALatest Information Update: 08 Jan 2025
At a glance
- Originator Cellectar Biosciences; LegoChem Biosciences
- Developer Cellectar Biosciences; LigaChem Biosciences
- Class Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 04 Jan 2022 LCB 09A is available for licensing as of 04 Jan 2022. https://www.legochembio.com/rnd/partners.php?lang=e
- 04 Jan 2022 Early research in Unspecified in South Korea (Parenteral), prior to January 2022 (LegoChem Biosciences pipeline, January 2022)
- 04 Jan 2022 Early research in Unspecified in USA (Parenteral), prior to January 2022 (LegoChem Biosciences pipeline, January 2022)